# Co expression of EGFR and CD10 in patients with phyllodes tumors of the breast: a single center experience in North Western Algeria

## TL;DR

This study examines the expression of EGFR and CD10 in breast phyllodes tumors to identify their role in diagnosis and prognosis.

## Contribution

The study explores the co-expression of EGFR and CD10 in phyllodes tumors as a potential diagnostic and prognostic marker.

## Key findings

- Only malignant phyllodes tumors showed EGFR expression.
- Coexistence of CD10 and EGFR overexpression was found in 25% of cases and was associated with age, tumor size, and histologic type.
- Patient age and tumor histology significantly correlate with CD10 and EGFR expression.

## Abstract

Breast phyllodes tumors (BPT) have variable malignant potential, their histological classification remains insufficient for an accurate diagnosis.

We attempted to investigate CD10 (Cluster of differentiation 10) and EGFR (Epidermal growth factor receptor) expression in BPT in order to highlight their diagnostic and prognostic values.

Eight patients with BPT are recruited from January 2014 to December 2020 and immunohistochemical assessment of CD10 and EGFR is realized.

Median age was 27±15.2, the mean tumor size was 9.63±10.21. Only malignant tumours showed expression for EGFR. Borderline and malignant tumors were CD10 positive. Patients overexpressing CD10 were postmenopausal with great tumor size, 25% of these were sarcomatous. Coexistence of CD10 and EGFR overexpression was found in 25% of cases and was associated with age (P=0.008), tumor size (P=0.030) and hitologic types (P=0.014). PC1 and PC2, were extracted, they accounted cumulatively for 94.7% of the variance of the data analysed, it suggests that patient's age and histological type of tumor have significant association with CD10 and EGFR expression in BPT.

EGFR and CD10 overexpressed combined proteins in phyllode tumors constitute, with histopathological parameters, an important prognostic factor as well as a promising potential targets.